Search

Your search keyword '"Ürün, Yüksel"' showing total 328 results
Start Over Author "Ürün, Yüksel"
328 results on '"Ürün, Yüksel"'

2. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

Author

Fiala, Ondřej, Massari, Francesco, Basso, Umberto, Giannatempo, Patrizia, Grande, Enrique, Buti, Sebastiano, Myint, Zin W., De Giorgi, Ugo, Pichler, Renate, Grillone, Francesco, Ürün, Yüksel, Calabrò, Fabio, Bourlon, Maria T., Galli, Luca, Kanesvaran, Ravindran, Roviello, Giandomenico, Kucharz, Jakub, Rizzo, Mimma, Park, Se Hoon, Cerbone, Linda, Seront, Emmanuel, Messina, Carlo, Molina-Cerrillo, Javier, Santini, Daniele, Yano, Akihiro, Incorvaia, Lorena, Catalano, Martina, Pinto, Alvaro, Formisano, Luigi, Soares, Andrey, Facchini, Gaetano, Fornarini, Giuseppe, Poprach, Alexandr, Rebuzzi, Sara Elena, Nasso, Cecilia, Spinelli, Gian Paolo, Angel, Martin, Stellato, Marco, Tural, Deniz, Aurilio, Gaetano, Epstein, Ilana, Carrozza, Francesco, Monteiro, Fernando Sabino Marques, Benedetti, Giovanni, Büchler, Tomáš, Ortega, Cinzia, Zakopoulou, Roubini, Battelli, Nicola, Porta, Camillo, Bellmunt, Joaquin, Gupta, Shilpa, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

3. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project

Author

Rizzo, Alessandro, Monteiro, Fernando Sabino Marques, Ürün, Yüksel, Massari, Francesco, Park, Se Hoon, Bourlon, Maria T., Poprach, Alexandr, Rizzo, Mimma, Takeshita, Hideki, Giannatempo, Patrizia, Soares, Andrey, Roviello, Giandomenico, Molina-Cerrillo, Javier, Carrozza, Francesco, Abahssain, Halima, Messina, Carlo, Kopp, Ray Manneh, Pichler, Renate, Formisano, Luigi, Tural, Deniz, Atzori, Francesco, Calabrò, Fabio, Kanesvaran, Ravindran, Buti, Sebastiano, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

4. Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study

Author

Sekmek, Serhat, Karahan, Irfan, Ucar, Gokhan, Ceylan, Furkan, Bayram, Dogan, Seven, Ismet, Bölek, Hatice, Ürün, Yüksel, Yücel, Kadriye Bir, Yazici, Ozan, Kadioglu, Ahmet, Karacin, Cengiz, Canaslan, Kubra, Atag, Elif, Demirer, Serhat, Erdem, Gokmen Umut, Ergun, Yakup, Atak, Mehmetcan, Koksal, Baris, Kiran, Merve Meryem, Turkay, Duriye Ozer, Civelek, Burak, Yalcin, Bulent, and Uncu, Dogan

Published
2024
Full Text
View/download PDF

6. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

Author

Yasar, Hatime Arzu, Aktas, Burak Yasin, Ucar, Gokhan, Goksu, Sema Sezgin, Bilgetekin, Irem, Cakar, Burcu, Sakin, Abdullah, Ates, Ozturk, Basoglu, Tugba, Arslan, Cagatay, Demiray, Atike Gokcen, Paydas, Semra, Cicin, Irfan, Sendur, Mehmet Ali Nahit, Karadurmus, Nuri, Kosku, Hakan, Uner, Aytuğ, Yumuk, Perran Fulden, Utkan, Gungor, Kefeli, Umut, Tanriverdi, Ozgur, Cinkir, Havva, Gumusay, Ozge, Turhal, Nazım Serdal, Menekse, Serkan, Kut, Engin, Beypinar, Ismail, Sakalar, Teoman, Demir, Hacer, Yekeduz, Emre, Kilickap, Saadettin, Erman, Mustafa, and Urun, Yuksel

Published
2024
Full Text
View/download PDF

9. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Author

Yekedüz, Emre, Özbay, Mehmet Fatih, Çağlayan, Dilek, Yıldırım, Atila, Erol, Cihan, Yıldırım, Hasan Çağrı, Tunç, Sezai, Özyurt, Neslihan, Özdemir, Feyyaz, Şendur, Mehmet Ali Nahit, Işıkdoğan, Abdurrahman, Kılıçkap, Saadettin, Ürün, Yüksel, Yalçın, Şuayib, Artaç, Mehmet, Coşkun, Hasan Şenol, and Utkan, Güngör

Published
2022
Full Text
View/download PDF

10. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Author

Yekedüz, Emre, Tural, Deniz, Ertürk, İsmail, Karakaya, Serdar, Erol, Cihan, Ercelep, Özlem, Arslan, Çağatay, Sever, Özlem Nuray, Kılıçkap, Saadettin, Şentürk Öztaş, Nihan, Küçükarda, Ahmet, Can, Orçun, Öksüzoğlu, Berna, Şendur, Mehmet Ali, Karadurmuş, Nuri, and Ürün, Yüksel

Published
2022
Full Text
View/download PDF

13. Primary Prostatic Stromal Sarcoma: A Case Report and Review of the Literature.

Author

Erul, Enes, Gülpınar, Ömer, Kuru Öz, Diğdem, Berber, Havva, Kiremitci, Saba, and Ürün, Yüksel

Subjects
DIGITAL rectal examination, MAGNETIC resonance imaging, RADICAL prostatectomy, CANCER relapse, SURGICAL excision
Abstract

Background and Objectives: Primary prostatic stromal sarcoma is an exceptionally rare urological malignancy, constituting less than 0.1% of all prostatic cancers. It poses a significant clinical challenge due to its aggressive behavior and poor prognosis. Materials and Methods: We report the case of a 34-year-old male who presented with nonspecific lower urinary tract symptoms, including dysuria and increased urinary frequency. The initial diagnostic workup, including digital rectal examination and Magnetic Resonance Imaging (MRI), revealed a lobulated lesion within the prostate. A transurethral resection (TUR) was performed for diagnostic purposes, and histopathological examination revealed a "malignant mesenchymal tumor". The patient underwent a laparoscopic radical prostatectomy. The pathology report confirmed the diagnosis of prostatic stromal sarcoma. The postoperative follow-up, including systemic CT and MRI, showed no evidence of recurrence or metastasis thus far. Results: Multidisciplinary management is essential for optimizing treatment outcomes in all urologic malignancies; however, it becomes particularly challenging and crucial in rare cases such as primary prostatic stromal sarcoma. In our case, the patient benefited from a coordinated approach involving urology, pathology, and oncology, underscoring the importance of collaborative care for rare and aggressive tumors like this. This case highlights the importance of early detection, complete surgical excision, and consideration of adjuvant therapies, given the aggressive nature of the disease. The role of novel therapeutic strategies, including immunotherapy and targeted therapies, is also discussed in the context of metastatic sarcomas. Conclusions: This case underscores the critical need for a comprehensive, multidisciplinary approach to managing primary prostatic stromal sarcoma. Ongoing research on innovative therapies offers hope for improved outcomes in metastatic stages. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Author

Yücel, Kadriye Bir, Yekedüz, Emre, Karakaya, Serdar, Tural, Deniz, Ertürk, İsmail, Erol, Cihan, Ercelep, Özlem, Öztaş, Nihan Şentürk, Arslan, Çağatay, Uçar, Gökhan, Küçükarda, Ahmet, Sever, Özlem Nuray, Kılıçkap, Saadettin, Can, Orçun, Yazgan, Satı Coşkun, Öksüzoğlu, Berna, Karadurmuş, Nuri, Şendur, Mehmet Ali, and Ürün, Yüksel

Published
2022
Full Text
View/download PDF

16. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).

Author

Chi, Kim N., primary, Agarwal, Neeraj, additional, Armstrong, Andrew J., additional, Hellmis, Eva, additional, Schlürmann, Friederike, additional, Sugimoto, Mikio, additional, Ürün, Yüksel, additional, Xing, Nianzeng, additional, Aregay, Mehreteab, additional, Lima, Julianne, additional, Meulendijks, Didier, additional, and Azad, Arun, additional

Published
2024
Full Text
View/download PDF

17. Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.

Author

Galsky, Matt D., primary, Sonpavde, Guru P., additional, Powles, Thomas, additional, Claps, Melanie, additional, Burotto, Mauricio, additional, Schenker, Michael, additional, Sade, Juan Pablo, additional, Bamias, Aristotelis, additional, Beuzeboc, Philippe, additional, Bedke, Jens, additional, Oldenburg, Jan, additional, Ürün, Yüksel, additional, Ye, Ding-Wei, additional, Valderrama, Begoña Pérez, additional, Tomita, Yoshihiko, additional, Filian, Jeiry, additional, Wang, Lily, additional, Purcea, Daniela, additional, and Van Der Heijden, Michiel Simon, additional

Published
2024
Full Text
View/download PDF

19. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Author

Tural, Deniz, Ölmez, Ömer Fatih, Sümbül, Ahmet Taner, Özhan, Nail, Çakar, Burcu, Köstek, Osman, Ekenel, Meltem, Erman, Mustafa, Coşkun, Hasan Şenol, Selçukbiricik, Fatih, Keskin, Özge, Türköz, Fatma Paksoy, Oruç, Kerem, Bayram, Selami, Bilgetekin, İrem, Yıldız, Birol, Şendur, Mehmet Ali Nahit, Paksoy, Nail, Dirican, Ahmet, Erdem, Dilek, Selam, Meltem, Tanrıverdi, Özgür, Paydaş, Semra, Urakçı, Zuhat, Atağ, Elif, Güncan, Sabri, Ürün, Yüksel, Alkan, Ali, Kaya, Ali Osman, Özyükseler, Deniz Tataroğlu, Taşkaynatan, Halil, Yıldırım, Mustafa, Sönmez, Müge, Başoğlu, Tuğba, Gündüz, Şeyda, Kılıçkap, Saadettin, and Artaç, Mehmet

Published
2021
Full Text
View/download PDF

20. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.

Author

Fiala, Ondřej, Massari, Francesco, Basso, Umberto, Giannatempo, Patrizia, Grande, Enrique, Buti, Sebastiano, Myint, Zin W., De Giorgi, Ugo, Pichler, Renate, Grillone, Francesco, Ürün, Yüksel, Calabrò, Fabio, Bourlon, Maria T., Galli, Luca, Kanesvaran, Ravindran, Roviello, Giandomenico, Kucharz, Jakub, Rizzo, Mimma, Park, Se Hoon, and Cerbone, Linda

Abstract

Background: Enfortumab vedotin (EV) has been approved for the treatment of patients with locally advanced/metastatic urothelial carcinoma (la/mUC) who previously received platinum-based chemotherapy followed by immune checkpoint inhibitors. However, the pivotal clinical trials did not include patients previously treated with avelumab maintenance therapy. Objective: The aim of the present retrospective analysis was to assess the effectiveness of EV following avelumab in patients with mUC enrolled in the ARON-2EV study. Patients and Methods: The study included 182 patients with mUC treated with EV following avelumab maintenance. The primary objective was to assess clinical outcomes, including progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and duration of response (DoR). Statistical analysis involved Fisher exact test, Kaplan–Meier method, log-rank test, and univariate/multivariate Cox proportional hazard regression models. Results: Median OS and PFS were 12.7 (95% CI 10.2–14.1) and 7.9 (95% CI 6.4–9.9) months, respectively. Complete response (CR) was achieved in 5% and partial response (PR) in 34% of patients, with an ORR of 39%. The DoR in patients who achieved CR/PR was 10.9 months (95% CI 8.1–11.4). The incidence of grade ≥ 3 peripheral neuropathy and skin rash was 9%, followed by 8% of grade ≥ 3 diarrhea and 4% of grade ≥ 3 hyperglycemia. Conclusions: The results of our large international retrospective study confirm the effectiveness of EV and endorse its use in the population of patients with mUC treated with EV following the frontline platinum-based chemotherapy and subsequent maintenance treatment with avelumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma.

Author

Bolek, Hatice, Yazgan, Satı Coskun, Yekedüz, Emre, and Ürün, Yüksel

Subjects
THERAPEUTIC use of antineoplastic agents, BLADDER tumors, PLATINUM compounds, COMBINATION drug therapy, CISPLATIN, IMMUNOTHERAPY, PATHOLOGIC complete response, TREATMENT effectiveness, META-analysis, CANCER patients, DESCRIPTIVE statistics, TRANSITIONAL cell carcinoma, METASTASIS, CANCER chemotherapy, MONOCLONAL antibodies, COMBINED modality therapy, GEMCITABINE, PROGRESSION-free survival, COMPARATIVE studies, OVERALL survival, EVALUATION
Abstract

The therapeutic landscape for metastatic urothelial carcinoma (mUC) has evolved significantly due to the development of innovative combination treatments, including enfortumab vedotin-pembrolizumab (EVP). Despite these advancements, the limited availability of EVP means that platinum-based chemotherapy regimens continue to serve as the primary treatment modality for many patients with mUC. We evaluated the effect of the type of platinum chemotherapy used in combination with immunotherapy (IO) on treatment outcomes in mUC. The meta-analysis showed that cisplatin-gemcitabine plus IO combination and carboplatin-gemcitabine plus IO combination improve progression-free survival compared to platinum-gemcitabine therapy (hazard ratio [HR] = 0.71, 95% CI: 0.62-0.82; P  < .0001 and HR = 0.85, 95% CI: 0.73-0.98; P  < .03, respectively). However, only the cisplatin-gemcitabine plus IO combination showed overall survival (OS) benefit (HR = 0.80, 95% CI: 0.69-0.93; P  < .003). In comparison to the platinum-gemcitabine combination, neither the cisplatin-gemcitabine plus IO nor the carboplatin-gemcitabine plus IO combinations demonstrated an objective response rate (ORR) benefit. In summary, combining cisplatin-gemcitabine with immunotherapy offers significant overall survival benefits in mUC. The exact mechanisms—whether cisplatin's immunomodulatory effects or patient demographic differences—are yet to be determined, necessitating further research to understand these outcomes better. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. PD34-11 NIVOLUMAB PLUS GEMCITABINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA: RESULTS OF ANALYSES TO CHARACTERIZE BENEFIT IN RESPONDERS FROM THE PHASE 3 CHECKMATE 901 TRIAL

Author

Sonpavde, Guru, primary, van der Heijden, Michiel S., additional, Powles, Thomas, additional, Necchi, Andrea, additional, Burotto, Mauricio, additional, Schenker, Michael, additional, Sade, Juan Pablo, additional, Bamias, Aristotelis, additional, Beuzeboc, Philippe, additional, Bedke, Jens, additional, Oldenburg, Jan, additional, Ürün, Yüksel, additional, Ye, Dingwei, additional, Valderrama, Begoña P., additional, Tomita, Yoshihiko, additional, Filian, Jeiry, additional, Wang, Lily, additional, Purcea, Daniela, additional, Nasroulah, Federico, additional, and Galsky, Matthew D., additional

Published
2024
Full Text
View/download PDF

25. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

35. A Case of Diffuse Infiltrative Hepatocellular Carcinoma with Marked Response to Sorafenib Treatment Evidenced by 18F-FDG PET/MRI.

Author

Özkan, Elgin, Demir, Burak, Öz, Diğdem Kuru, Ürün, Yüksel, and Küçük, Nuriye Özlem

Subjects
POSITRON emission tomography computed tomography, MAGNETIC resonance imaging, CHRONIC hepatitis B, POSITRON emission tomography, HEPATOCELLULAR carcinoma
Abstract

Copyright of Molecular Imaging & Radionuclide Therapy is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

38. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Author

van der Heijden, Michiel S., primary, Sonpavde, Guru, additional, Powles, Thomas, additional, Necchi, Andrea, additional, Burotto, Mauricio, additional, Schenker, Michael, additional, Sade, Juan Pablo, additional, Bamias, Aristotelis, additional, Beuzeboc, Philippe, additional, Bedke, Jens, additional, Oldenburg, Jan, additional, Chatta, Gurkamal, additional, Ürün, Yüksel, additional, Ye, Dingwei, additional, He, Zhisong, additional, Valderrama, Begoña P., additional, Ku, Ja Hyeon, additional, Tomita, Yoshihiko, additional, Filian, Jeiry, additional, Wang, Lily, additional, Purcea, Daniela, additional, Patel, Miraj Y., additional, Nasroulah, Federico, additional, and Galsky, Matthew D., additional

Published
2023
Full Text
View/download PDF

39. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Author

Ünal, Çağlar, primary, Azizy, Abdulmunir, additional, Karabulut, Senem, additional, Taştekin, Didem, additional, Akyıldız, Arif, additional, Yaşar, Serkan, additional, Yalçın, Şuayib, additional, Çoban, Eyüp, additional, Evrensel, Türkkan, additional, Kalkan, Ziya, additional, Oruç, Zeynep, additional, Derin, Sümeyra, additional, Turna, Zeynep Hande, additional, Bayram, Doğan, additional, Köş, Fahriye Tuğba, additional, Şendur, Mehmet Ali Nihat, additional, Sever, Nadiye, additional, Ercelep, Özlem, additional, Seyyar, Mustafa, additional, Kefeli, Umut, additional, Uygun, Kazım, additional, Özçelik, Melike, additional, Ön, Sercan, additional, Şanlı, Ulus Ali, additional, Canaslan, Kübra, additional, Ünek, İlkay Tuba, additional, Yücel, Kadriye Bir, additional, Özdemir, Nuriye, additional, Yazıcı, Ozan, additional, Güzel, Halil Göksel, additional, Salim, Derya Kıvrak, additional, Göksu, Sema Sezgin, additional, Tatlı, Ali Murat, additional, Ordu, Çetin, additional, Selvi, Oğuzhan, additional, Sakin, Abdullah, additional, Büyükbayram, Mehmet Emin, additional, Dursun, Bengü, additional, Ürün, Yüksel, additional, Arak, Hacı, additional, Ağdaş, Gözde, additional, Uğraklı, Muzaffer, additional, Hendem, Engin, additional, Eryılmaz, Melek Karakurt, additional, Bilgin, Burak, additional, Topçu, Atakan, additional, Şimşek, Melih, additional, Büyükşimşek, Mahmut, additional, Akay, Büşra, additional, Erdal, Gülçin Şahingöz, additional, Karataş, Fatih, additional, Alan, Özkan, additional, Çağlayan, Melek, additional, Kahvecioğlu, Fatma Akdağ, additional, Demirci, Ayşe, additional, Paksoy, Nail, additional, Çetin, Bülent, additional, Gümüş, Mahmut, additional, Ak, Naziye, additional, Aydınalp, Yasemin, additional, Paydaş, Semra, additional, Güven, Deniz Can, additional, Kılıçkap, Saadettin, additional, and Sağlam, Sezer, additional

Published
2023
Full Text
View/download PDF

41. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

42. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, Omlin, Aurelius, and O’Sullivan, Joe M.

Subjects
Cancer Research, Systemic therapy, Next-generation imaging, Metastatic castration-resistant prostate cancer (mCRPC) and oligometastatic and oligoprogressive prostate cancer, Metastatic hormone-sensitive prostate cancer (mHSPC), Medizin, PSMA PET-imaging, All institutes and research themes of the Radboud University Medical Center, Oncology, Androgen receptor pathway inhibitors (ARPI), SDG 3 - Good Health and Well-being, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Non metastatic castration-resistant prostate cancer (nmCRPC), Chemotherapy, Hormonal treatment
Abstract

BackgroundInnovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence.ObjectiveTo present the voting results of the APCCC 2022.Design, setting, and participantsThe experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions.Outcome measurements and statistical analysisThe panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions.Results and limitationsThe voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer.ConclusionsThese voting results in four specific areas from a panel of experts in advanced prostate cancer can help clinicians and patients navigate controversial areas of management for which high-level evidence is scant or conflicting and can help research funders and policy makers identify information gaps and consider what areas to explore further. However, diagnostic and treatment decisions always have to be individualised based on patient characteristics, including the extent and location of disease, prior treatment(s), co-morbidities, patient preferences, and treatment recommendations and should also incorporate current and emerging clinical evidence and logistic and economic factors. Enrolment in clinical trials is strongly encouraged. Importantly, APCCC 2022 once again identified important gaps where there is non-consensus and that merit evaluation in specifically designed trials.

Published
2023
Full Text
View/download PDF

43. Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.

Author

Balli, Sevinc, Bolek, Hatice, and Ürün, Yüksel

Abstract

Recent progress in adjuvant immunotherapy offers hope for improving disease-free survival in high-risk bladder cancer (BC) and renal cell carcinoma (RCC). This review focuses on key trials such as CheckMate 274 and KEYNOTE-564, which show promising results with nivolumab in BC and pembrolizumab in RCC, including a 30% reduction in progression risk. Pembrolizumab also demonstrated overall survival (OS) benefit in RCC. The review also explores the potential of circulating tumor DNA (ctDNA) as a biomarker for better therapy selection and patient stratification. It emphasizes the need for ongoing research to establish survival benefits and suggests integrating biomarkers and risk stratification to optimize adjuvant immunotherapy in BC and RCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer.

Author

Alkan, Ali, Mızrak, Dilşa, Yaşar, Arzu, Karcı, Ebru, Köksoy, Elif Berna, Ürün, Muslih, Özyurt, Neslihan, Kuştaş, Ali Aytuğ, Kütük, Tuğçe, Ürün, Yüksel, Şenler, Filiz Çay, Akyürek, Serap, Utkan, Güngör, Demirkazık, Ahmet, Gökçe, Şaban Çakır, and Akbulut, Hakan

Subjects
STOMACH cancer, ADJUVANT chemotherapy, OVERALL survival, NEPHROTOXICOLOGY, CANCER radiotherapy
Abstract

Introduction: Adjuvant chemoradiotherapy (CRT) is the optimal management strategy in resectable gastric cancer. There is a debate about the efficacy of more aggressive CRT plus chemotherapy regimens in adjuvant setting. This study aimed to compare the efficacy of adjuvant CRT plus docetaxel-cisplatin-fluorouracil (DCF) versus CRT plus fluorouracil-folinic acid (FUFA) in stage III gastric cancer. Methods: Patients with a diagnosis of stage III gastric cancer treated with adjuvant therapy after curative resection were analyzed. Patients’ disease characteristics and impacts of the regimens on median disease‑free survival (DFS) and median overall survival (OS) were analyzed retrospectively. Results: One hundred sixty‑one patients (102 in FUFA arm and 59 in DCF arm) with a median age of 56.0 (29-79) were evaluated. In the DCF arm, there were more renal toxicities (31.6% vs 6.4% P < 0.001), emergency department admissions (64.9% vs 23.7%, P < 0.001), and dose reductions/treatment modifications in the DCF arm (51.6% vs 37.2, P < 0.001). The median follow‑up was 23 months (1-124) in the FUFA arm and 26.0 months (1-77) in the DCF arm. The median DFS was 25.0 months (%95 CI, 12.7-37.2) in the DCF arm and 17.0 months(%95 CI, 2.6-31.3) in the FUFA arm, P = 0.66. The median OS was 28.0 months (%95 CI, 17.0-38.9) in the DCF arm and 25.0 months (%95 CI, 11.9-36.0) in the FUFA arm, P = 0.70. Conclusion: In conclusion, when compared with FUFA regimen, more aggressive therapy with DCF was more toxic and did not improve OS in adjuvant setting of stage III gastric cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Management of Patients with Advanced Prostate Cancer. Part I:Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, Omlin, Aurelius, Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Abstract

Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical man

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results